Impact of MDM2 Gene Polymorphism on Sarcoma Risk

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Nov 5

PMID 25366142

Citations 1

Authors

Dawei Zhang

Yuanyuan Ding

Zhenlin Wang

Yan Wang

Guangyue Zhao

Affiliations

Soon will be listed here.

Abstract

A T>G single nucleotide polymorphism (SNP, rs2279744) of the MDM2 gene has been investigated in sarcoma community, but the findings are conflicting. This study was designed to well define the relationship between SNP rs2279744 and sarcoma risk. We did a systematic computerized search of the PubMed, Web of Science, and Science Direct databases to identify the human case-control studies investigating the relationship between SNP rs2279744 and sarcoma risk with complete genetic data. Pooled odds ratios (ORs) were calculated with the Mantel-Haenszel fixed-effect model or the DerSimonian and Laird random effects model to estimate the risk of sarcoma. Overall analysis included five independent studies. On the whole, the T/G genotype or the combined G/G and T/G genotypes appeared to be associated with approximately 1.40-fold higher risk of sarcoma relative to the T/T genotype (T/G vs. T/T: OR 1.33, 95% CI 1.00-1.77; G/G + T/G vs. T/T: OR 1.42, 95% CI 1.08-1.85). We noted that the Caucasian populations showed a similarly increased risk of sarcoma ascribed to the carriage of the same genotypes (T/G vs. T/T: OR 1.41, 95% CI 1.05-1.90; G/G + T/G vs. T/T: OR 1.49, 95% CI 1.13-1.97). This meta-analysis provides evidence that MDM2 SNP rs2279744 may be significantly associated with increased risk of sarcoma in Caucasian individuals.

Citing Articles

Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.

Benna C, Simioni A, Pasquali S, De Boni D, Rajendran S, Spiro G Oncotarget. 2018; 9(26):18607-18626.

PMID: 29719630 PMC: 5915097. DOI: 10.18632/oncotarget.24719.

References

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Leach F, Tokino T, Meltzer P, Burrell M, Oliner J, Smith S . p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53(10 Suppl):2231-4. View

Dorfman H, Czerniak B . Bone cancers. Cancer. 1995; 75(1 Suppl):203-10. DOI: 10.1002/1097-0142(19950101)75:1+<203::aid-cncr2820751308>3.0.co;2-v. View

Cai X, Yang M . The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol. 2011; 138(4):555-61. DOI: 10.1007/s00432-011-1124-8. View

Moll U, Petrenko O . The MDM2-p53 interaction. Mol Cancer Res. 2004; 1(14):1001-8. View

Harbord R, Egger M, Sterne J . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2005; 25(20):3443-57. DOI: 10.1002/sim.2380. View

Onel K, Cordon-Cardo C . MDM2 and prognosis. Mol Cancer Res. 2004; 2(1):1-8. View

Birgander R, Sjalander A, Saha N, Spitsyn V, Beckman L, BECKMAN G . The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum Hered. 1996; 46(3):148-54. DOI: 10.1159/000154344. View

FREEDMAN D, Wu L, Levine A . Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999; 55(1):96-107. PMC: 11146946. DOI: 10.1007/s000180050273. View

10.

Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger C . Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009; 15(10):3550-6. DOI: 10.1158/1078-0432.CCR-08-2249. View

11.

Grady W, Markowitz S . Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002; 3:101-28. DOI: 10.1146/annurev.genom.3.022502.103043. View

12.

Jones S, Hancock A, Vogel H, Donehower L, Bradley A . Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998; 95(26):15608-12. PMC: 28091. DOI: 10.1073/pnas.95.26.15608. View

13.

Borden E, Baker L, Bell R, Bramwell V, Demetri G, Eisenberg B . Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003; 9(6):1941-56. View

14.

Huang S, Chen I, Liao C, Wang H, Liou S, Hsieh L . Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol. 2008; 45(1):16-22. DOI: 10.1016/j.oraloncology.2008.03.006. View

15.

Bond G, Hu W, Levine A . A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005; 65(13):5481-4. DOI: 10.1158/0008-5472.CAN-05-0825. View

16.

Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

17.

FREEDMAN D, Levine A . Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999; 59(1):1-7. View

18.

Ruijs M, Schmidt M, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R . The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2006; 15(1):110-4. DOI: 10.1038/sj.ejhg.5201715. View

19.

Greenblatt M, BENNETT W, Hollstein M, Harris C . Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54(18):4855-78. View

20.

Michael D, Oren M . The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003; 13(1):49-58. DOI: 10.1016/s1044-579x(02)00099-8. View